Published in Nature on September 05, 2002
Aptamers as therapeutics. Nat Rev Drug Discov (2010) 5.36
Triggers, targets and treatments for thrombosis. Nature (2008) 3.51
In vivo activity of nuclease-resistant siRNAs. RNA (2004) 2.33
Development of universal antidotes to control aptamer activity. Nat Med (2009) 1.93
Frameworks for programming biological function through RNA parts and devices. Chem Biol (2009) 1.74
Rapid identification of cell-specific, internalizing RNA aptamers with bioinformatics analyses of a cell-based aptamer selection. PLoS One (2012) 1.60
Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3. Proc Natl Acad Sci U S A (2003) 1.54
A high affinity, antidote-controllable prothrombin and thrombin-binding RNA aptamer inhibits thrombin generation and thrombin activity. J Thromb Haemost (2012) 1.54
Molecular assembly for high-performance bivalent nucleic acid inhibitor. Proc Natl Acad Sci U S A (2008) 1.44
Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer. Chem Biol (2008) 1.42
Microarray methods for protein biomarker detection. Analyst (2008) 1.40
Creating advanced multifunctional biosensors with surface enzymatic transformations. Langmuir (2006) 1.35
Crystal structure of an RNA aptamer bound to thrombin. RNA (2008) 1.32
Fabrication and characterization of RNA aptamer microarrays for the study of protein-aptamer interactions with SPR imaging. Nucleic Acids Res (2006) 1.30
Nucleic acid aptamers: clinical applications and promising new horizons. Curr Med Chem (2011) 1.30
Rational truncation of an RNA aptamer to prostate-specific membrane antigen using computational structural modeling. Nucleic Acid Ther (2011) 1.16
Nucleotide bias observed with a short SELEX RNA aptamer library. Nucleic Acid Ther (2011) 1.15
Current progress of RNA aptamer-based therapeutics. Front Genet (2012) 1.12
Large scale analysis of the mutational landscape in HT-SELEX improves aptamer discovery. Nucleic Acids Res (2015) 1.11
Aptamers selected against the unglycosylated EGFRvIII ectodomain and delivered intracellularly reduce membrane-bound EGFRvIII and induce apoptosis. Biol Chem (2009) 1.05
Intracellular delivery of RNA-based therapeutics using aptamers. Ther Deliv (2010) 1.05
Rational design of low-molecular weight heparins with improved in vivo activity. Proc Natl Acad Sci U S A (2003) 1.04
Using photons to manipulate enzyme inhibition by an azobenzene-modified nucleic acid probe. Proc Natl Acad Sci U S A (2009) 0.98
Molecular imaging with nucleic acid aptamers. Curr Med Chem (2011) 0.96
An anticoagulant RNA aptamer that inhibits proteinase-cofactor interactions within prothrombinase. J Biol Chem (2009) 0.95
Aptamers in virology: recent advances and challenges. Front Microbiol (2012) 0.95
A cancer cell-activatable aptamer-reporter system for one-step assay of circulating tumor cells. Mol Ther Nucleic Acids (2014) 0.92
Nucleic acid aptamers for targeting of shRNA-based cancer therapeutics. Biologics (2007) 0.92
Emulsion PCR: a high efficient way of PCR amplification of random DNA libraries in aptamer selection. PLoS One (2011) 0.91
Tumor-targeted drug delivery with aptamers. Curr Med Chem (2011) 0.91
Aptamers: problems, solutions and prospects. Acta Naturae (2013) 0.90
Aptamer that binds to the gD protein of herpes simplex virus 1 and efficiently inhibits viral entry. J Virol (2012) 0.88
Isolation of specific and high-affinity RNA aptamers against NS3 helicase domain of hepatitis C virus. RNA (2004) 0.88
Waveguide-mode sensors as aptasensors. Sensors (Basel) (2012) 0.88
Potent anticoagulant aptamer directed against factor IXa blocks macromolecular substrate interaction. J Biol Chem (2012) 0.88
Spiegelzymes: sequence specific hydrolysis of L-RNA with mirror image hammerhead ribozymes and DNAzymes. PLoS One (2013) 0.87
Spiegelzymes® mirror-image hammerhead ribozymes and mirror-image DNAzymes, an alternative to siRNAs and microRNAs to cleave mRNAs in vivo? PLoS One (2014) 0.85
Identification of TIM3 2'-fluoro oligonucleotide aptamer by HT-SELEX for cancer immunotherapy. Oncotarget (2016) 0.85
Strategies for the discovery of therapeutic aptamers. Expert Opin Drug Discov (2011) 0.84
Aptamers as therapeutics in cardiovascular diseases. Curr Med Chem (2011) 0.84
Inhibiting the intrinsic pathway of coagulation with a factor XII-targeting RNA aptamer. J Thromb Haemost (2013) 0.84
Aptamer photoregulation in vivo. Proc Natl Acad Sci U S A (2014) 0.84
Targeting inhibition of GluR1 Ser845 phosphorylation with an RNA aptamer that blocks AMPA receptor trafficking. J Neurochem (2008) 0.83
RNA plasticity and selectivity applicable to therapeutics and novel biosensor development. Genes Cells (2012) 0.82
Polymeric drugs: Advances in the development of pharmacologically active polymers. J Control Release (2015) 0.81
In vitro evolution of chemically-modified nucleic acid aptamers: Pros and cons, and comprehensive selection strategies. RNA Biol (2016) 0.81
Screening of DNA aptamer against mouse prion protein by competitive selection. Prion (2007) 0.81
Aptamers as a novel tool for diagnostics and therapy. Invest New Drugs (2015) 0.80
Conformationally selective RNA aptamers allosterically modulate the β2-adrenoceptor. Nat Chem Biol (2016) 0.80
Selection of an aptamer antidote to the anticoagulant drug bivalirudin. PLoS One (2013) 0.80
Aptamers as both drugs and drug-carriers. Biomed Res Int (2014) 0.79
Molecular Selection, Modification and Development of Therapeutic Oligonucleotide Aptamers. Int J Mol Sci (2016) 0.78
Oligonucleotide aptamers: A next-generation technology for the capture and detection of circulating tumor cells. Methods (2015) 0.78
RNA as drug and antidote. Nature (2002) 0.78
Probing the coagulation pathway with aptamers identifies combinations that synergistically inhibit blood clot formation. Chem Biol (2014) 0.77
Smart functional nucleic acid chimeras: enabling tissue specific RNA targeting therapy. RNA Biol (2015) 0.77
From selection hits to clinical leads: progress in aptamer discovery. Mol Ther Methods Clin Dev (2016) 0.77
The REG1 anticoagulation system: a novel actively controlled factor IX inhibitor using RNA aptamer technology for treatment of acute coronary syndrome. Future Cardiol (2012) 0.77
A reversible aptamer improves outcome and safety in murine models of stroke and hemorrhage. Oligonucleotides (2010) 0.76
Oligonucleotide-Based Systems for Input-Controlled and Non-Covalently Regulated Protein-Binding. Supramol Chem (2013) 0.76
Effects of plasminogen activator inhibitor-1-specific RNA aptamers on cell adhesion, motility, and tube formation. Nucleic Acid Ther (2011) 0.76
Modulation of the Coagulation Cascade Using Aptamers. Arterioscler Thromb Vasc Biol (2015) 0.76
Method for Confirming Cytoplasmic Delivery of RNA Aptamers. Methods Mol Biol (2016) 0.76
A ssDNA Aptamer That Blocks the Function of the Anti-FLAG M2 Antibody. J Nucleic Acids (2011) 0.76
Targeting Two Coagulation Cascade Proteases with a Bivalent Aptamer Yields a Potent and Antidote-Controllable Anticoagulant. Nucleic Acid Ther (2015) 0.76
In vitro RNA SELEX for the generation of chemically-optimized therapeutic RNA drugs. Methods (2016) 0.75
Aptamers in Therapeutics. J Clin Diagn Res (2016) 0.75
Theranostic DNAzymes. Theranostics (2017) 0.75
Selection and characterization of a DNA aptamer inhibiting coagulation factor XIa. Sci Rep (2017) 0.75
Differential Contributions of Intrinsic and Extrinsic Pathways to Thrombin Generation in Adult, Maternal and Cord Plasma Samples. PLoS One (2016) 0.75
Selection and Characterization of an α6β4 Integrin blocking DNA Aptamer. Mol Ther Nucleic Acids (2016) 0.75
Translation and Clinical Development of Antithrombotic Aptamers. Nucleic Acid Ther (2016) 0.75
Simultaneous targeting of CD44 and EpCAM with a bispecific aptamer effectively inhibits intraperitoneal ovarian cancer growth. Theranostics (2017) 0.75
A novel IgY-Aptamer hybrid system for cost-effective detection of SEB and its evaluation on food and clinical samples. Sci Rep (2015) 0.75
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med (2015) 10.86
Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science (2005) 9.04
A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med (2013) 7.09
Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol (2006) 6.30
Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med (2010) 5.23
Aptamers: an emerging class of therapeutics. Annu Rev Med (2005) 4.15
Evolution of adverse changes in stored RBCs. Proc Natl Acad Sci U S A (2007) 3.58
Effect of escitalopram on mental stress-induced myocardial ischemia: results of the REMIT trial. JAMA (2013) 3.48
Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med (2006) 3.11
Notch promotes radioresistance of glioma stem cells. Stem Cells (2010) 3.07
Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review. Ann Intern Med (2012) 3.04
Effects of red-cell storage duration on patients undergoing cardiac surgery. N Engl J Med (2015) 3.03
Venous thromboembolism: a public health concern. Am J Prev Med (2010) 2.37
In vivo activity of nuclease-resistant siRNAs. RNA (2004) 2.33
Comparison of characteristics from White- and Black-Americans with venous thromboembolism: a cross-sectional study. Am J Hematol (2010) 2.26
Antidote-mediated control of an anticoagulant aptamer in vivo. Nat Biotechnol (2004) 2.18
Comparative effectiveness of new oral anticoagulants and standard thromboprophylaxis in patients having total hip or knee replacement: a systematic review. Ann Intern Med (2013) 2.15
Development of universal antidotes to control aptamer activity. Nat Med (2009) 1.93
Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol (2012) 1.85
Anti-heparin/platelet factor 4 antibody optical density values and the confirmatory procedure in the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost (2008) 1.61
Aspirin exposure reveals novel genes associated with platelet function and cardiovascular events. J Am Coll Cardiol (2013) 1.61
Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia. Blood (2010) 1.55
FVIIa as used pharmacologically is not TF dependent in hemophilia B mice. Blood (2014) 1.50
Plasmapheresis and heparin reexposure as a management strategy for cardiac surgical patients with heparin-induced thrombocytopenia. Anesth Analg (2009) 1.49
Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J Clin Oncol (2009) 1.45
Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer. Chem Biol (2008) 1.42
Randomized trial of physician alerts for thromboprophylaxis after discharge. Am J Med (2013) 1.39
RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells. Mol Ther (2008) 1.38
Blockade of tissue factor: treatment for organ injury in established sepsis. Am J Respir Crit Care Med (2003) 1.38
In vivo selection of tumor-targeting RNA motifs. Nat Chem Biol (2009) 1.36
Assays for measuring rivaroxaban: their suitability and limitations. Ther Drug Monit (2010) 1.36
Prevalence and clinical characteristics of mental stress-induced myocardial ischemia in patients with coronary heart disease. J Am Coll Cardiol (2013) 1.34
Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2. Proc Natl Acad Sci U S A (2003) 1.32
Crystal structure of an RNA aptamer bound to thrombin. RNA (2008) 1.32
Blockade of tissue factor-factor X binding attenuates sepsis-induced respiratory and renal failure. Am J Physiol Lung Cell Mol Physiol (2005) 1.31
Depressive symptoms and mental stress-induced myocardial ischemia in patients with coronary heart disease. Psychosom Med (2013) 1.24
Simultaneous generation of aptamers to multiple gamma-carboxyglutamic acid proteins from a focused aptamer library using DeSELEX and convergent selection. Oligonucleotides (2007) 1.20
High incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypass. Blood (2013) 1.16
RNA aptamer-targeted inhibition of NF-kappa B suppresses non-small cell lung cancer resistance to doxorubicin. Mol Ther (2007) 1.14
A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery. Mol Ther (2006) 1.13
Retracted Gene-expression patterns predict phenotypes of immune-mediated thrombosis. Blood (2005) 1.12
H1 RNA polymerase III promoter-driven expression of an RNA aptamer leads to high-level inhibition of intracellular protein activity. Nucleic Acids Res (2006) 1.09
Functional repair of a mutant chloride channel using a trans-splicing ribozyme. J Clin Invest (2002) 1.07
Optimizing aptamer activity for gene therapy applications using expression cassette SELEX. Mol Ther (2002) 1.06
Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost (2012) 1.06
Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome. Blood (2004) 1.06
Aptamers selected against the unglycosylated EGFRvIII ectodomain and delivered intracellularly reduce membrane-bound EGFRvIII and induce apoptosis. Biol Chem (2009) 1.05
Inhibition of in vivo tumor angiogenesis and growth via systemic delivery of an angiopoietin 2-specific RNA aptamer. J Surg Res (2007) 1.05
Nucleic acid scavengers inhibit thrombosis without increasing bleeding. Proc Natl Acad Sci U S A (2012) 1.05
Clinical and laboratory diagnosis of von Willebrand disease: a synopsis of the 2008 NHLBI/NIH guidelines. Am J Hematol (2009) 1.05
Coagulation and inflammation in acute lung injury. Thromb Haemost (2002) 1.03
Hypercoagulable states and antithrombotic strategies in recurrent vascular access site thrombosis. J Vasc Surg (2003) 1.02
Venous thromboembolic disease. J Natl Compr Canc Netw (2013) 1.01
Distinct roles of E2F proteins in vascular smooth muscle cell proliferation and intimal hyperplasia. Proc Natl Acad Sci U S A (2007) 1.01
Antihuman factor V antibodies after use of relatively pure bovine thrombin. Ann Thorac Surg (2005) 1.01
Time-dependent changes in non-COX-1-dependent platelet function with daily aspirin therapy. J Thromb Thrombolysis (2012) 1.00
Targeted inhibition of alphavbeta3 integrin with an RNA aptamer impairs endothelial cell growth and survival. Biochem Biophys Res Commun (2005) 1.00
Heparin modifies the immunogenicity of positively charged proteins. Blood (2010) 1.00
Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008). Kidney Int Suppl (2009) 1.00
The potential of aptamers as anticoagulants. Trends Cardiovasc Med (2005) 1.00
The kaolin-activated Thrombelastograph predicts bleeding after cardiac surgery. J Cardiothorac Vasc Anesth (2006) 0.98
Venous thromboembolic disease. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2006) 0.98
Synergistic effect of aptamers that inhibit exosites 1 and 2 on thrombin. RNA (2009) 0.98
Nucleic acid-binding polymers as anti-inflammatory agents. Proc Natl Acad Sci U S A (2011) 0.98
Associations of depressive symptoms, trait hostility, and gender with C-reactive protein and interleukin-6 response after emotion recall. Psychosom Med (2010) 0.98
Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project. J Am Coll Cardiol (2007) 0.97
Efficient and specific repair of sickle beta-globin RNA by trans-splicing ribozymes. RNA (2003) 0.97
Ribozyme-mediated induction of apoptosis in human cancer cells by targeted repair of mutant p53 RNA. Mol Ther (2004) 0.96
Heparin-induced thrombocytopenia. Annu Rev Med (2010) 0.95
An anticoagulant RNA aptamer that inhibits proteinase-cofactor interactions within prothrombinase. J Biol Chem (2009) 0.95
Coagulation abnormalities in patients with hip osteonecrosis. Orthop Clin North Am (2004) 0.95
Notch signaling in cancer stem cells. Adv Exp Med Biol (2012) 0.95
Using 5'-PTMs to repair mutant beta-globin transcripts. RNA (2007) 0.94
What is wrong with the allosteric disulfide bond hypothesis? Arterioscler Thromb Vasc Biol (2009) 0.94
Low-molecular-weight heparin for thromboprophylaxis in pregnant women with mechanical heart valves. J Matern Fetal Neonatal Med (2006) 0.93
RNA aptamer to thrombin binds anion-binding exosite-2 and alters protease inhibition by heparin-binding serpins. FEBS Lett (2004) 0.93
Antimetastatic potential of PAI-1-specific RNA aptamers. Oligonucleotides (2009) 0.93
Venous thromboembolic disease. J Natl Compr Canc Netw (2011) 0.93
Comparing human pancreatic cell secretomes by in vitro aptamer selection identifies cyclophilin B as a candidate pancreatic cancer biomarker. J Clin Invest (2012) 0.92
Frequency of anti-heparin-platelet factor 4 antibodies in hemodialysis patients and correlation with recurrent vascular access thrombosis. Am J Hematol (2002) 0.91
NF-kappaB inhibition by an adenovirus expressed aptamer sensitizes TNFalpha-induced apoptosis. Biochem Biophys Res Commun (2007) 0.91
Thrombophilias: when should we test and how does it help? Semin Respir Crit Care Med (2008) 0.90
Ribozyme-mediated revision of RNA and DNA. J Clin Invest (2003) 0.90
Superactivated platelets: thrombus regulators, thrombin generators, and potential clinical targets. Arterioscler Thromb Vasc Biol (2013) 0.89
Aptamers in immunotherapy. Hum Gene Ther (2008) 0.89
Whole blood gene expression analyses in patients with single versus recurrent venous thromboembolism. Thromb Res (2011) 0.88
Aptamer-mediated delivery of splice-switching oligonucleotides to the nuclei of cancer cells. Nucleic Acid Ther (2012) 0.88
Hyperreactive platelet phenotypes: relationship to altered serotonin transporter number, transport kinetics and intrinsic response to adrenergic co-stimulation. Thromb Haemost (2012) 0.88
Thrombosis, thrombophilia, and thromboprophylaxis in pregnancy. Clin Adv Hematol Oncol (2005) 0.87
Aptamer-mediated delivery of chemotherapy to pancreatic cancer cells. Nucleic Acid Ther (2012) 0.87
Activated B cells modified by electroporation of multiple mRNAs encoding immune stimulatory molecules are comparable to mature dendritic cells in inducing in vitro antigen-specific T-cell responses. Immunology (2008) 0.87
Antithrombotic therapy and invasive procedures. N Engl J Med (2013) 0.87
Venous thromboembolic disease. NCCN. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2008) 0.87
Direct-to-patient expert system and home INR monitoring improves control of oral anticoagulation. J Thromb Thrombolysis (2007) 0.87
Warfarin in antiphospholipid syndrome--time to explore new horizons. J Rheumatol (2005) 0.86